hyftor
plusultra pharma gmbh - sirolimus - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
oxynorm dispersa (oxynorm) munndreifitafla 20 mg
mundipharma a/s - oxycodonum hýdróklóríð - munndreifitafla - 20 mg
oxynorm dispersa (oxynorm) munndreifitafla 5 mg
mundipharma a/s - oxycodonum hýdróklóríð - munndreifitafla - 5 mg
mirtazapin bluefish munndreifitafla 15 mg
bluefish pharmaceuticals ab - mirtazapinum inn - munndreifitafla - 15 mg
míron smelt munndreifitafla 15 mg
teva b.v.* - mirtazapinum inn - munndreifitafla - 15 mg
míron smelt munndreifitafla 30 mg
teva b.v.* - mirtazapinum inn - munndreifitafla - 30 mg
mirtazapin bluefish munndreifitafla 30 mg
bluefish pharmaceuticals ab - mirtazapinum inn - munndreifitafla - 30 mg
rizatriptan alvogen (rizatriptan portfarma) munndreifitafla 10 mg
alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 10 mg
rizatriptan alvogen (rizatriptan portfarma) munndreifitafla 5 mg
alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 5 mg
rizatriptan sumar pharma (rizatriptan ratiopharm) munndreifitafla 10 mg
alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 10 mg